Biotech | November 20, 2021
Novo Nordisk to acquire Dicerna Pharmaceuticals for US $ 3.3 bn
Dicerna develops RNAi-based therapies to selectively silence genes that cause or contribute to disease
Dicerna develops RNAi-based therapies to selectively silence genes that cause or contribute to disease
Betting big on talent, resources, and the ecosystem required for innovation and enterprise, Prime Minister Narendra Modi invited stakeholders to ideate in India, innovate in India and Make in India for the world
The cream has an estimated market size of US $ 28 million for twelve months ending Jun 2021 according to IQVIA
Two out of three people under the age of 40 are at risk of prediabetes
The interim data combines three mRNAs into one therapy injected directly into the tumour
Data demonstrates Ronapreve reduced risk of hospitalisation in certain patients and reduced risk of symptomatic Covid-19 infections in people exposed to the virus
The centre has an initial capacity of 500 FTEs
The consideration for the acquisition is US $ 2.25 million
_256_384.png)
Cryoballoon catheter ablation, a minimally invasive procedure, is one of the therapeutic modalities to manage Atrial fibrillation
Molnupiravir is an investigational oral antiviral medicine, for the treatment of mild-to-moderate COVID-19 in at risk adults
Subscribe To Our Newsletter & Stay Updated
